Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CDC7 | O00311 | 1/20 | 0.51 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.51 |
| ▸ | CBFB | Q13951 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 4/20 | 0.49 |
| ▸ | METAP1 | P53582 | 4/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5396525 | 0.86 | GSK3B (0.71) | GSK3BKMT2ACDC7CBFBMETAP2 | |
| SCHEMBL5384455 | 0.85 | GSK3B (0.75) | GSK3BKMT2ACDC7DBF4CYP19A1 | |
| SCHEMBL14935666 | 0.84 | GSK3B (0.73) | GSK3BKMT2ACDC7DBF4CYP19A1 | |
| SCHEMBL13611987 | 0.84 | LMNA (0.54) | GSK3BKMT2ACBFBMETAP2METAP1 | |
| SCHEMBL5381426 | 0.81 | GSK3B (0.78) | GSK3BKMT2ACDC7DBF4CYP19A1 | |
| SCHEMBL5376063 | 0.80 | GSK3B (0.76) | GSK3BKMT2ACDC7DBF4CYP19A1 | |
| SCHEMBL5390774 | 0.80 | GSK3B (0.66) | GSK3BKMT2ACDC7DBF4NPC1 | |
| [2,3'']Bipyridinyl SCHEMBL29360744 | 0.77 | CYP2A6 (1.00) | CYP2A6METAP2METAP1CYP19A1PIM1 | |
| [2,3'']Bipyridinyl SCHEMBL29486847 | 0.77 | CYP2A6 (1.00) | CYP2A6METAP2METAP1CYP19A1PIM1 | |
| [2,3'']Bipyridinyl SCHEMBL29389597 | 0.77 | CYP2A6 (1.00) | CYP2A6METAP2METAP1CYP19A1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231642-B1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| EP-2044056-B1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | disclosed |
| EP-2231642-A1 | PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| WO-2009087224-A1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| EP-2044056-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | Novartis Ag (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006583-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| EP-1878733-A1 | Pyrimidine derivatives as ALK-5 inhibitors | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298337-A1 | Organic Compounds | CYP11B2, TNNT2, CPT1B | CYP2A6 221/4885GSK3B 2457/4885KMT2A 3490/4885 |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | ALK, ACVR1, MUSK | CYP2A6 1225/4885GSK3B 2623/4885KMT2A 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.